This application aims to develop a novel strategy for preventing chronic myeloid leukemia (CML) by targeting leukemia stem cells (LSCs) that initiate CML. This idea is based on our recently published finding that the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) is a key survival-regulatory gene in LSCs (Chen et al. Nature Genetics 41:783-792, 2009), suggesting that Alox5 serves as a potential target gene for preventing CML. A known function of 5-LO is to produce inflammatory leukotrienes, and enzymatic activity of 5-LO can be inhibited by an FDA-approved human anti-inflammatory drug Zileuton (Zyflo). Thus, Zileuton could be a promising chemopreventive agent for CML;the underlying mechanisms are totally unknown and could be related to the effects of Zileuton on the known metabolic function or novel functions of Alox5 or both. Our preliminary studies also show that Zileuton suppresses human CML stem cells. Because CML is derived from a stem cell harboring the BCR-ABL oncogene, our findings prompt us to hypothesize that Zileuton acts on an Alox5-related molecular network responsible for survival regulation of LSCs and is a potential chemopreventive agent for CML. Testing this hypothesis is of clinical significance and would benefit: 1) individuals who have detectable BCR-ABL transcripts but have not developed CML;2) CML patients who are in molecular remission and hope or have to stop a BCR-ABL kinase inhibitor;and 3) CML patients who had bone marrow transplantation but may still have residual leukemia cells. Mechanistically, because the known Alox5 function is to produce leukotrienes, Zileuton may prevent CML by reducing their production, which needs to be tested. Our preliminary data also reveal novel functions of Alox5, suggesting that Zileuton may suppress Alox5 function through regulating pathways unrelated to production of leukotrienes. In this regard, our preliminary study in shows that loss of P-selectin causes upregulation of Hif1a which enhances Alox5 expression in LSCs and that Alox5 signals to beta-catenin. Inhibition of LSCs by Zileuton provides a novel preventive strategy for CML. In-depth study of Zileuton function helps to identify more Alox5-related target genes for preventing CML and provides a rationale for modifying existing drugs with activities on Alox5 and related genes.
The specific aims are: 1) To determine whether leukotrienes promote the survival of LSCs, whether Zileuton suppresses LSCs through reducing leukotriene production and what the underlying mechanism is;2) To determine the intracellular pathways affected by Zileuton in LSCs;and 3) To determine whether Zileuton similarly regulates the Alox5 pathway in human CML stem cells and reduces engraftment of human CML cells in immunocompromised mice. Although we focus on CML, Zileuton is also a potential chemopreventive agent for solid tumors as Alox5 is associated with carcinogenesis in the colon, lung, pancreas, liver, esophagus, skin.
We aim to understand the mechanism by which a FDA-approved anti-inflammatory drug (Zileuton) works to prevent initiation of chromic myeloid leukemia (CML). We have identified a key gene known as Alox5 in leukemia stem cells (LSCs) from which CML is derive, and CML does not develop without Alox5, indicating that Alox5 is critically required by LSCs for survival and CML initiation. Inhibition of Alox5 by Zileuton provides a novel strategy for preventing CML in some healthy individuals who have acquired CML-causing gene but have not developed the disease, in patients who are in remission and need to stop using kinase inhibitors and in patients who received bone marrow transplantation but still have detectable leukemia cells.
|Chen, Yaoyu; Shan, Yi; Lu, Min et al. (2017) Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. Cancer Res 77:164-174|
|Cheloni, Giulia; Tanturli, Michele; Tusa, Ignazia et al. (2017) Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood 130:655-665|
|Cheng, Hui; Hao, Sha; Liu, Yanfeng et al. (2015) Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood 126:1302-13|